Brexpiprazole (brand name Rexulti, previously known as OPC-34712) is a novel D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM) approved for the treatment of schizophrenia, and as an adjunctive treatment for depression.
Brexpiprazole (brand name Rexulti, previously known as OPC-34712) is a novel atypical antipsychotic drug. The drug received FDA approval on July 13,2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression.